Neovascular-targeted immunoconjugates
Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
1. A method for treating a patient with wet macular degeneration or a vascularized tumor, wherein the method comprises:
administering to the patient an effective amount of an immunoconjugate protein comprising a human IgG1 immunoglobulin Fc domain conjugated to a mutant form of human factor VII comprising the amino acid sequence encoded by the nucleotide sequence at positions 202-1419 of SEQ ID NO: 12.
2. The method of claim 1 wherein the patient has wet macular degeneration.
3. The method of claim 1 wherein the patient has a vascularized tumor.
4. The method of claim 1 wherein the step of administering is intravenous.
5. The method of claim 2 wherein the administering is intraocular.
6. The method of claim 3 wherein the step of administering is via intratumoral injection.
7. The method of claim 1 wherein the step of administering is local.
8. A method for treating a patient bearing a vascularized tumor which expresses tissue factor, wherein the method comprises:
administering to the patient bearing the vascularized tumor an effective amount of an immunoconjugate protein comprising a human IgG1 immunoglobulin Fc domain conjugated to a mutant form of human factor VII comprising the amino acid sequence encoded by the nucleotide sequence at positions 202-1419 of SEQ ID NO: 12.
9. The method of claim 8 wherein the patient has metastatic disease.
10. The method of claim 8 wherein the tumor is a melanoma.
11. The method of claim 8 wherein the tumor is a lung tumor.